ANTARES PHARMA INC (ATRS)
US0366421065 - Common Stock
We assign a fundamental rating of 3 out of 10 to ATRS. ATRS was compared to 198 industry peers in the Pharmaceuticals industry. The financial health of ATRS is average, but there are quite some concerns on its profitability. ATRS is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
ATRS had positive earnings in the past year.
In multiple years ATRS reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: ATRS reported negative operating cash flow in multiple years.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.97% | ||
| ROE | 26.33% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.87% | ||
| PM (TTM) | 25.15% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for ATRS has been increased compared to 1 year ago.
ATRS has a better debt/assets ratio than last year.
2.2 Solvency
ATRS has an Altman-Z score of 8.15. This indicates that ATRS is financially healthy and has little risk of bankruptcy at the moment.
ATRS has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.15 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 2.96 indicates that ATRS has no problem at all paying its short term obligations.
A Quick Ratio of 2.76 indicates that ATRS has no problem at all paying its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.96 | ||
| Quick Ratio | 2.76 |
3. Growth
3.1 Past
ATRS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 350.00%, which is quite impressive.
The Revenue has grown by 22.99% in the past year. This is a very strong growth!
Measured over the past years, ATRS shows a very strong growth in Revenue. The Revenue has been growing by 28.65% on average per year.
EPS 1Y (TTM)350%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q533.33%
Revenue 1Y (TTM)22.99%
Revenue growth 3Y42.49%
Revenue growth 5Y28.65%
Revenue growth Q2Q10.42%
3.2 Future
Based on estimates for the next years, ATRS will show a very strong growth in Earnings Per Share. The EPS will grow by 41.76% on average per year.
ATRS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.75% yearly.
EPS Next Y-69.78%
EPS Next 2Y-9.18%
EPS Next 3Y8.49%
EPS Next 5Y41.76%
Revenue Next Year15.42%
Revenue Next 2Y18.38%
Revenue Next 3Y17.73%
Revenue Next 5Y17.75%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 20.70, which indicates a rather expensive current valuation of ATRS.
ATRS is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 24.55, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 68.50 indicates a quite expensive valuation of ATRS.
When comparing the Price/Forward Earnings ratio of ATRS to the average of the S&P500 Index (20.92), we can say ATRS is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.7 | ||
| Fwd PE | 68.5 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 29.05 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.18%
EPS Next 3Y8.49%
5. Dividend
5.1 Amount
No dividends for ATRS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ANTARES PHARMA INC
NASDAQ:ATRS (5/23/2022, 7:12:09 PM)
After market: 5.59 0 (0%)5.59
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap955.06M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.7 | ||
| Fwd PE | 68.5 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.97% | ||
| ROE | 26.33% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 14.87% | ||
| PM (TTM) | 25.15% | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.71
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.96 | ||
| Quick Ratio | 2.76 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)350%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-69.78%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)22.99%
Revenue growth 3Y42.49%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y